MedPath

SwanBio Therapeutics, Inc.

SwanBio Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2017-01-01
Employees
11
Market Cap
-
Website
http://www.swanbiotx.com

Clinical Trials

2

Active:2
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)

Phase 1
Active, not recruiting
Conditions
X-ALD
AMN Gene Mutation
AMN
First Posted Date
2022-05-27
Last Posted Date
2025-06-27
Lead Sponsor
SwanBio Therapeutics, Inc.
Target Recruit Count
16
Registration Number
NCT05394064
Locations
🇺🇸

University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States

🇳🇱

Amsterdam UMC, Amsterdam, Netherlands

Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia

Active, not recruiting
Conditions
AMN Gene Mutation
AMN
X-ALD
First Posted Date
2021-08-17
Last Posted Date
2023-09-13
Lead Sponsor
SwanBio Therapeutics, Inc.
Target Recruit Count
65
Registration Number
NCT05008874
Locations
🇺🇸

Stanford Neuroscience Health Center, Stanford, California, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Weill Medical College of Cornell University, New York, New York, United States

and more 3 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.